GeneBio and Genedata Integrate Computational Platforms to Support Proteomics Projects
News Oct 26, 2005
The two companies will integrate the Genedata Expressionist® solution with the Melanie/ImageMasterä 2D Platinum solution, forming a seamless analysis workflow.
“There is a growing need for integrated, reproducible and scalable methods to exploit proteomics data,” explained Nasri Nahas, CEO of GeneBio.
“The next phase in the collaboration involves incorporating Expressionist with GeneBio’s Phenyx mass spectrometry (MS) data analysis platform, specifically designed to meet the concurrent demands of high-throughput MS data analysis and dynamic results assessment.”
“This collaboration builds on synergies between our systems and delivers robust automation of proteomics analysis.”
“We are pleased to have the opportunity to combine our high-throughput systems with GeneBio’s renowned proteomics software,” said Dr Daniel Keesman, CEO of Genedata AG.
Combined with the Melanie platform, the complete solution is suited to many high-throughput applications including biomarker-based preclinical research.
“Automating the validation and analysis of 2D gel data is just one example of how the collaboration will save time and expensive laboratory consumables in high-throughput proteomics.”
Genedata’s Expressionist® is designed to automate analysis workflows from sample validation through to biological interpretation and result management.
The Melanie two-dimensional gel electrophoresis (2-DE) analysis solution was developed by the Swiss Institute of Bioinformatics (SIB) and GeneBio; it now powers GE Healthcare’s ImageMasterä 2D Platinum platform.
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE